Delving into the Latest Updates on Hydroxyzine Hydrochloride with Synapse

Overview

Basic Info

SummaryHydroxyzine is a first-generation antihistamine that is commonly used for the treatment of various allergic conditions such as hives and itching. It works by blocking the action of histamine, a chemical released in response to an allergic reaction. Histamine causes symptoms such as itching, swelling, and rash. Hydroxyzine is available in oral and injectable formulations. It is generally well tolerated by patients. However, side effects can include drowsiness, dizziness and dry mouth. It is important to note that there is ongoing research regarding the potential use of hydroxyzine to treat anxiety disorders, as it has shown some anxiolytic activity in preclinical studies.

Drug Type

Small molecule drug

Synonyms

Hychotine, Hydroxine, Hydroxizine

+ [13]

Target

H1 receptor

Mechanism

H1 receptor antagonists(Histamine H1 receptor antagonists)

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal DiseasesOther Diseases

Active Indication

UrticariaAnxiety DisordersDepressive Disorder+ [2]

Inactive Indication

Pruritus

Originator Organization

Pfizer Inc.

Active Organization

Pfizer Inc.

Inactive Organization

Roerig SA

Drug Highest PhaseApproved

First Approval Date

US (12 Apr 1956),

Anxiety DisordersPruritusUrticaria

Regulation-

Login to view First Approval Timeline

Structure

Molecular FormulaC21H28Cl2N2O2

InChIKeyIPSVAUIEEPSJRZ-UHFFFAOYSA-N

CAS Registry2192-20-3

The aim of this study is to evaluate the efficacy of hydroxyzine compared to treatment as usual (TAU) for patients with panic disorder. By conducting a pilot study, we hope to provide initial data on the feasibility and potential impact of hydroxyzine for this population. This will inform the design and power calculations of a larger, more comprehensive study in the future.
Objectives:
To assess the feasibility of conducting a randomized controlled trial (RCT) of hydroxyzine for panic disorder.
To evaluate the effectiveness of hydroxyzine compared to TAU in reducing panic symptoms in patients with panic disorder.
To explore the potential side effects and tolerability of hydroxyzine in this population.
Methods:
This will be a single-center, open-label, randomized pilot study. A total of 30 patients with a primary diagnosis of panic disorder will be recruited from a psychiatric outpatient clinic. Participants will be randomly assigned to receive either hydroxyzine or TAU for 8 weeks. The primary outcome measure will be the change in panic symptoms as assessed by the Panic Disorder Severity Scale (PDSS). Secondary outcome measures will include the Hamilton Anxiety Rating Scale (HAM-A) and the Clinical Global Impression-Severity (CGI-S) scale. Participants will be assessed at baseline, 4 weeks, and 8 weeks. Adverse events will be monitored throughout the study.
Expected Results:
This pilot study is expected to provide preliminary data on the feasibility and potential efficacy of hydroxyzine for panic disorder. The results will inform the design of a larger RCT to further evaluate the efficacy of hydroxyzine for this population.
Significance:
There is a need for effective and well-tolerated treatments for panic disorder. If found to be effective, hydroxyzine could provide a new option for patients with this condition, potentially improving their quality of life and functioning. The results of this pilot study will inform the design of future studies and contribute to the development of evidence-based treatments for panic disorder.

Start Date30 Dec 2023

Sponsor / Collaborator

University of Sultan Qaboos

NCT05680584 / RecruitingPhase 1IIT

Comparison Between the Effect of Oral Melatonin and Hydroxyzine for Preventing Preoperative Anxiety in Pediatric Patients Undergoing Adenotonsillectomy

Comparison between the effect of oral Melatonin and Hydroxyzine for Preventing Preoperative Anxiety in pediatric Patients Undergoing Adenotonsillectomy

Start Date01 Feb 2023

Sponsor / Collaborator

Faculty Of Medicine Minia University

CTRI/2022/03/040739 / CompletedNot Applicable

A monocentric, single group study to evaluate the effect of Atarax cream in participants with pruritis.

Start Date04 Mar 2022

Sponsor / Collaborator

Dr. Reddy's Laboratories Ltd.

100 Clinical Results associated with Hydroxyzine Hydrochloride

Login to view more data

100 Translational Medicine associated with Hydroxyzine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Hydroxyzine Hydrochloride

Login to view more data

1,162

Literatures (Medical) associated with Hydroxyzine Hydrochloride

01 Jan 2024·Journal of pharmaceutical and biomedical analysis

Drugs detection in fingerprints

Article

Author: Bigosińska, Joanna ; Adamowicz, Piotr ; Tokarczyk, Bogdan ; Gil, Dominika ; Suchan, Marta

Fingerprints left at a crime scene are used to connect the crime to a person who may have been present there. Fingerprints can also be used as alternative material in forensic toxicology. The detection of drugs in fingerprint samples can be used to show that an individual touching an item has consumed specific drugs. The aim of this study was to check the usefulness of fingerprints in drug analyses and detection of some analytes in this material. Fingerprint samples were collected on glass slides from a volunteer who consumed separately tablets containing pseudoephedrine, codeine, dextromethorphan, and used lidocaine spray. Moreover, fingerprints of individuals receiving sertraline, hydroxyzine and trazodone as part of their long-term treatment were analysed. The detection of drugs was conducted using the liquid chromatography tandem mass spectrometry (LC-MS/MS) technique. After administration of single doses of drugs, they were detected up to 36 h (pseudoephedrine), 24 h (codeine), and less than 6 h (dextromethorphan and lidocaine) with maximum concentrations observed at 1-4 h. In fingerprints of a person who has finished treatment with hydroxyzine and sertraline it was possible to detect these drugs even 20 days after last drug administration. Cetirizine (hydroxyzine metabolite) and mCPP (trazodone metabolite) were determined in fingerprints of individuals under long-term treatment. This work has demonstrated that forensic toxicology can use fingerprints as alternative material. Drugs can be detected in fingerprints even after their single doses. Parent compounds predominate over metabolites in the fingerprints. The detection window depends on the type of drug and duration of the treatment.

18 Dec 2023·Cureus

Terbinafine-Induced Liver Injury: A Case Report

Author: Edwards, Brian P ; Brockman, Michael J ; Cazares Parson, Marco ; Jilani, Misbah ; Zaidi, Syed ; Hakim, Nawar

Hepatic injuries attributable to terbinafine usage are a well-documented yet infrequent phenomenon. This case study details the clinical presentation and management of a 70-year-old Hispanic female, with no previous medical history, subsequently hospitalized for progressive jaundice, right upper quadrant abdominal discomfort, and worsening pruritus. A comprehensive review of her prior records revealed a recent terbinafine prescription for onychomycosis, which she took consistently for five weeks and then self-discontinued four weeks before her current admission. Laboratory tests on admission revealed a cholestatic pattern of liver injury, evident by transaminitis and conjugated hyperbilirubinemia. The R factor used to determine whether a liver injury is hepatocellular or cholestatic was 0.9. Further diagnostic imaging, including abdominal ultrasound, CT of the abdomen, and magnetic resonance cholangiopancreatography, failed to disclose an obstructive pathology, revealing only cholelithiasis and chronic cholecystitis. Therapeutically, the patient was initiated on hydroxyzine to address symptoms of pruritus, and then subsequently underwent a liver biopsy. Histopathologic findings from the biopsy revealed benign hepatic parenchyma demonstrating focal canalicular cholestasis, mild chronic inflammation involving select portal tracts, and chronic lobular inflammation, suggesting terbinafine-induced hepatotoxicity. This case highlights the challenges of diagnosing terbinafine-induced liver injury, emphasizing the need for a high index of clinical suspicion and recognizing the potential for prolonged symptomatic manifestation after drug discontinuation. This article provides valuable insights into the complexities inherent in such diagnoses and significantly enriches a medical provider's approach to diagnosing and treating unexplained liver injuries.

29 Nov 2023·Cureus

Psychological Testing in a Complex Case: Psychosis in Co-occurring PTSD, Gender Dysphoria, and Bipolar Disorder

Author: Sperry, Susan D ; Megna, James L ; Ansari, Maliha I ; Leontieva, Luba

This case report investigates the concurrent presence of post-traumatic stress disorder (PTSD) and bipolar disorder (BD) in the transgender population. We present a case involving a 21-year-old female-to-male transgender individual (preferred pronouns - they/them). The patient had a history of psychosis, trauma, gender dysphoria (GD), inconsistent hormone (testosterone) treatments, and a self-attributed diagnosis of "associative identity disorder" with 21 distinct "identities." They had two emergency admissions in quick succession, both characterized by analogous symptoms. Contributing factors included a recent discontinuation of antipsychotic medications and a history of cannabis use. Their family history included BD in the patient's mother and schizophrenia in their paternal grandfather. The differential diagnoses considered were brief psychosis, BD, PTSD, and substance-induced mania/psychosis. A notable improvement in the patient's clinical presentation was observed during their hospital stay. Their therapeutic regimen comprised olanzapine, hydroxyzine, topiramate, trazodone, and lithium carbonate extended-release. Additionally, the patient underwent psychological testing. This progress solidified the primary diagnosis as PTSD coexisting with BD, manifesting episodes of mania and psychosis. This report highlights the critical role of psychological evaluations in assessing symptoms in patients with multiple psychiatric co-morbidities. Our findings emphasize the importance of a comprehensive, multidisciplinary approach for accurate diagnosis and efficacious treatment of such intricate cases.

100 Deals associated with Hydroxyzine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00672	Hydroxyzine Hydrochloride	N05BB01	DB00557

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Depressive Disorder	JP	Pfizer Inc.	30 Sep 1965
Eczema	JP	Pfizer Inc.	30 Sep 1965
Nausea and vomiting	JP	Pfizer Inc.	30 Sep 1965
Anxiety Disorders	US	Pfizer Inc.	12 Apr 1956
Pruritus	US	Pfizer Inc.	12 Apr 1956
Urticaria	US	Pfizer Inc.	12 Apr 1956

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04068948 (CTgov)	Phase 4	Sedation \| Dental Caries	37	Meperidine+Hydroxyzine+Midazolam (Midazolam, Hydroxyzine, Meperidine)	gjdfdqyvbd(nurejihrrj) = stvpqoclcj pssetdsywo (adkbrdmksw, siqvnlrjhu - ihshybxtjj) View more	-	05 Dec 2023
NCT04068948 (CTgov)	Phase 4	Sedation \| Dental Caries	37	Hydroxyzine+Midazolam (Midazolam, Hydroxyzine)	gjdfdqyvbd(nurejihrrj) = vmcadfjuyz pssetdsywo (adkbrdmksw, rbbxxswqdk - swmqigtvea) View more	-	05 Dec 2023
NCT04188106 (CTgov)	Phase 4	Nausea \| Dyssomnias \| Smoking Cessation	26	Varenicline Pill+Hydroxyzine Pill	qqldtpqqpo(byieqdzjep) = eihhjzbfef hcnzbgkngf (crniprfsyr, ipheyusesj - fctjculmla) View more	-	03 Mar 2023
ASCO2005	Not Applicable	Ostealgia	-	G-CSF administration	fowqexiusx(phruixzxsp) = The bone pain frequently emerges as one of the side effects of G-CSF administration. Rising pressure within bone marrow by increased granulocytes, edema within bone marrow by histamine release, and increased level of bradykinin are thought to be the mechanisms underlying it. The incidence of bone pain is reported to be 1–5% of all cases, but in practice we have the impression that there have been more cases with bone pain, some of which are resistant to treatment with non-steroid anti-inflammatory drugs (NSAIDs). mnpybhecky (lnckumnifw )	-	01 Jun 2005